ASH 2022 Conference Coverage: Focus on GVHD for Pharmacists
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell ...
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of ...
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic ...
At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of ...
In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence ...
Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was ...
In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on ...
Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to ...
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and ...
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved ...
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy ...
For years, the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic cell ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.